BresaGen executes supply contracts
Friday, 27 January, 2006
Adelaide biotechnology manufacturer BresaGen (ASX:BGN) has executed supply contracts worth AUD$680,000 with WA based junior biotech Caldeon and Brisbane's Tissue Therapies (ASX:TIS).
Caldeon is collaborating with the University of Western Australia to optimise osteoporosis drug leads which could reduce bone loss.
BresaGen offers process development and manufacture of recombinant peptides and proteins providing an alternative to peptide manufacture using chemical synthesis. The company has a proprietary fusion protein system that allows high level expression and inclusion body formation of proteins and peptides in E. Coli.
BresaGen has now provided several Australian biotech companies with process development and supply of material for various stages of product development including, CBio, Hunter Immunology, QRx, Imugene (ASX:IMU) and Psiron (ASX:PSX).
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
